Ecuador vs Somalia: Average cost of multi drug-resistant tuberculosis treatment
Ecuador
1,121 constant 2022 US$
in 2024
Somalia
1,178 constant 2022 US$
in 2021
Ecuador rank
42nd
Somalia rank
40th
Average cost of multi drug-resistant tuberculosis treatment over time
- Ecuador
- Somalia
How they compare
Somalia currently reports 1,178 constant 2022 US$ against 1,121 constant 2022 US$ in Ecuador, a difference of 57 constant 2022 US$.
That makes Somalia's figure about 1.1 times Ecuador's.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Ecuador ahead.
Ecuador ranks 42nd and Somalia ranks 40th of 92 countries.
Somalia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ecuador | Somalia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 754 constant 2022 US$ | 1,490 constant 2022 US$ | 735.67 constant 2022 US$ | Somalia |
| 2020s | 1,261 constant 2022 US$ | 1,340 constant 2022 US$ | 79.5 constant 2022 US$ | Somalia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Ecuador or Somalia?
- Somalia, at 1,178 constant 2022 US$ against 1,121 constant 2022 US$ in Ecuador as of 2021.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Ecuador and Somalia?
- 57 constant 2022 US$, with Somalia ahead.
- How many years of comparable data are there for Ecuador and Somalia?
- 5 years are reported by both, from 2017 to 2021.
- How do Ecuador and Somalia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Ecuador ranks 42nd and Somalia ranks 40th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.